Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 107 people in total across three groups, divided based on a genetic marker in their cancer cells called "1q21 amplification" — a change in a specific chromosome that some myeloma (a type of blood cancer) patients have. There were 26 people whose cancer cells had this marker (1q21 Amplified), 72 who did not have it (1q21 Not Amplified), and 9 whose test either failed or was missing. The trial was measuring how participants' myeloma responded to a combination treatment called PAD (made up of three medicines: bortezomib, doxorubicin, and dexamethasone), both after the treatment itself and then again three months after a stem cell transplant. The reported data shows that for the main measurement — how many people showed a meaningful reduction in their myeloma after four rounds of PAD treatment — 91 out of 107 participants were counted as responders overall. Breaking this down by group: 63 out of the 1q21 Not Amplified group, 20 out of the 1q21 Amplified group, and 8 from the failed/missing test group responded. The reported data also shows that three months after a stem cell transplant, 85 participants overall were recorded as responders (58 in the Not Amplified group, 20 in the Amplified group, and 7 in the failed/missing group). For survival figures measured two years after starting treatment, 93.8% of the Not Amplified group and 86.4% of the Amplified group were reported as still alive, while 75.0% of the Not Amplified group and 69.6% of the Amplified group were reported as free from events such as disease worsening, death, or serious complications. The "Failed/Missing Test" group was not included in the survival figures as reported. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Myeloma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have previously been diagnosed with multiple myeloma
- Your doctor has determined that you are suitable for a stem cell transplant using your own stem cells (called an autologous stem cell transplant)
- Your recent blood or lab test results meet certain levels required by the trial (confirm with trial site for specific values)
Who may not be able to join:
- You have already received treatment for multiple myeloma, such as radiation therapy or high-dose steroid (dexamethasone) treatment — though very limited prior treatment may be acceptable, such as radiation to a single affected area or up to 4 days of steroid therapy (confirm with trial site)
- You have currently been diagnosed with a milder or related blood condition, such as smoldering multiple myeloma, MGUS (an early abnormal protein condition in the blood), or Waldenström Macroglobulinemia
- You have had another type of cancer at any point in the last 5 years before joining the trial
- You have other serious health conditions alongside your myeloma diagnosis (confirm with trial site for specific details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen-Cilag Pty Ltd Clinical Trial, Janssen-Cilag Pty Ltd
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
16 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.